A TCR recognizing the melanoma antigenic peptide MART-1:27–35 was chosen for initial studies, since MART-1 is expressed by most melanomas and the epitope is restricted by the predominant MHC allele expressed in the United States, HLA-A2. This evidence concerns the gene HLA-C and melanoma.